体外评估由外源酶的α-鼠李糖酶激活的新型 SN-38 原药。

IF 1.8 4区 化学 Q3 CHEMISTRY, ANALYTICAL
Teruki Nii, Shoichi Hijii, Ryosuke Kaneko, Kenta Tanito, Kota Yamanaka, Akihiro Kishimura, Takeshi Mori, Yoshiki Katayama
{"title":"体外评估由外源酶的α-鼠李糖酶激活的新型 SN-38 原药。","authors":"Teruki Nii,&nbsp;Shoichi Hijii,&nbsp;Ryosuke Kaneko,&nbsp;Kenta Tanito,&nbsp;Kota Yamanaka,&nbsp;Akihiro Kishimura,&nbsp;Takeshi Mori,&nbsp;Yoshiki Katayama","doi":"10.1007/s44211-024-00593-9","DOIUrl":null,"url":null,"abstract":"<div><p>This study introduces the α-rhamnose (Rham)-conjugated prodrug of SN-38 (Rham-SN-38) as a promising alternative to irinotecan. α-rhamnosidase, responsible for SN-38 release from Rham-SN-38, does not express in human cells, minimizing individual variability and side effects. The injection of the α-rhamnosidase into the tumor tissues makes it possible, for the first time, to activate the Rham-SN-38. Furthermore, α-rhamnosidase demonstrates significantly higher activity than carboxylesterase, the specific enzyme activating irinotecan. SN-38 release mediated by α-rhamnosidase completes within 2 h, with a <i>k</i><sub><i>cat</i></sub>/K<sub>m</sub> value approximately 5.0 × 10<sup>4</sup>-fold higher than that of irinotecan. The 50% inhibition concentration (IC<sub>50</sub>) of Rham-SN-38 against three types of cancer cells and one normal cell exceeds 4.5 × 10<sup>3</sup> nM. The addition of α-rhamnosidase significantly increases cytotoxicity, with IC<sub>50</sub> comparable to free SN-38. The QIC<sub>50</sub>, an index reflecting the difference in cytotoxicity with and without α-rhamnosidase, exceeds approximately 1.0 × 10<sup>2</sup>-fold. Rham-SN-38, synthesized in this study, demonstrates significant potential as a prodrug for cancer therapy.</p><h3>Graphical abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":7802,"journal":{"name":"Analytical Sciences","volume":"40 8","pages":"1529 - 1535"},"PeriodicalIF":1.8000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In vitro evaluation of novel SN-38 prodrug activated by α-rhamnosidase of exogenous enzyme\",\"authors\":\"Teruki Nii,&nbsp;Shoichi Hijii,&nbsp;Ryosuke Kaneko,&nbsp;Kenta Tanito,&nbsp;Kota Yamanaka,&nbsp;Akihiro Kishimura,&nbsp;Takeshi Mori,&nbsp;Yoshiki Katayama\",\"doi\":\"10.1007/s44211-024-00593-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This study introduces the α-rhamnose (Rham)-conjugated prodrug of SN-38 (Rham-SN-38) as a promising alternative to irinotecan. α-rhamnosidase, responsible for SN-38 release from Rham-SN-38, does not express in human cells, minimizing individual variability and side effects. The injection of the α-rhamnosidase into the tumor tissues makes it possible, for the first time, to activate the Rham-SN-38. Furthermore, α-rhamnosidase demonstrates significantly higher activity than carboxylesterase, the specific enzyme activating irinotecan. SN-38 release mediated by α-rhamnosidase completes within 2 h, with a <i>k</i><sub><i>cat</i></sub>/K<sub>m</sub> value approximately 5.0 × 10<sup>4</sup>-fold higher than that of irinotecan. The 50% inhibition concentration (IC<sub>50</sub>) of Rham-SN-38 against three types of cancer cells and one normal cell exceeds 4.5 × 10<sup>3</sup> nM. The addition of α-rhamnosidase significantly increases cytotoxicity, with IC<sub>50</sub> comparable to free SN-38. The QIC<sub>50</sub>, an index reflecting the difference in cytotoxicity with and without α-rhamnosidase, exceeds approximately 1.0 × 10<sup>2</sup>-fold. Rham-SN-38, synthesized in this study, demonstrates significant potential as a prodrug for cancer therapy.</p><h3>Graphical abstract</h3>\\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>\",\"PeriodicalId\":7802,\"journal\":{\"name\":\"Analytical Sciences\",\"volume\":\"40 8\",\"pages\":\"1529 - 1535\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Analytical Sciences\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s44211-024-00593-9\",\"RegionNum\":4,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, ANALYTICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytical Sciences","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s44211-024-00593-9","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0

摘要

α-鼠李糖酶负责从 Rham-SN-38 中释放 SN-38,它在人体细胞中不表达,从而最大限度地减少了个体差异和副作用。将α-鼠李糖酶注射到肿瘤组织中首次实现了 Rham-SN-38 的活化。此外,α-鼠李糖酶的活性明显高于羧酸酯酶,后者是激活伊立替康的特异性酶。α-鼠李糖酶介导的 SN-38 释放在 2 小时内完成,其 kcat/Km 值约为伊立替康的 5.0 × 104 倍。Rham-SN-38 对三种癌细胞和一种正常细胞的 50% 抑制浓度(IC50)超过 4.5 × 103 nM。加入α-鼠李糖酶可显著增加细胞毒性,其 IC50 与游离 SN-38 相当。QIC50 是反映加入和不加入 α-鼠李糖酶时细胞毒性差异的指标,大约超过 1.0 × 102 倍。本研究合成的 Rham-SN-38 具有作为癌症治疗原药的巨大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

In vitro evaluation of novel SN-38 prodrug activated by α-rhamnosidase of exogenous enzyme

In vitro evaluation of novel SN-38 prodrug activated by α-rhamnosidase of exogenous enzyme

This study introduces the α-rhamnose (Rham)-conjugated prodrug of SN-38 (Rham-SN-38) as a promising alternative to irinotecan. α-rhamnosidase, responsible for SN-38 release from Rham-SN-38, does not express in human cells, minimizing individual variability and side effects. The injection of the α-rhamnosidase into the tumor tissues makes it possible, for the first time, to activate the Rham-SN-38. Furthermore, α-rhamnosidase demonstrates significantly higher activity than carboxylesterase, the specific enzyme activating irinotecan. SN-38 release mediated by α-rhamnosidase completes within 2 h, with a kcat/Km value approximately 5.0 × 104-fold higher than that of irinotecan. The 50% inhibition concentration (IC50) of Rham-SN-38 against three types of cancer cells and one normal cell exceeds 4.5 × 103 nM. The addition of α-rhamnosidase significantly increases cytotoxicity, with IC50 comparable to free SN-38. The QIC50, an index reflecting the difference in cytotoxicity with and without α-rhamnosidase, exceeds approximately 1.0 × 102-fold. Rham-SN-38, synthesized in this study, demonstrates significant potential as a prodrug for cancer therapy.

Graphical abstract

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Analytical Sciences
Analytical Sciences 化学-分析化学
CiteScore
2.90
自引率
18.80%
发文量
232
审稿时长
1 months
期刊介绍: Analytical Sciences is an international journal published monthly by The Japan Society for Analytical Chemistry. The journal publishes papers on all aspects of the theory and practice of analytical sciences, including fundamental and applied, inorganic and organic, wet chemical and instrumental methods. This publication is supported in part by the Grant-in-Aid for Publication of Scientific Research Result of the Japanese Ministry of Education, Culture, Sports, Science and Technology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信